Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The alpelisib (ALP) experience in the SOLAR-1 and BYLieve studies: Perspectives for practitioners caring for patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Meeting Abstract

    Rugo, H. S.; André, F.; Park, Y. H.; Drullinsky, P.; Loibl, S.; Cardoso, F.; Mason, G.; Aubel, D.; Lorenzo, I.; Akdere, M.; more...
    Breast (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC)
    Meeting Abstract

    Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S.; Boni, V.; Pelekanou, V.; Ternès, N.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Meeting Abstract

    Saura Manich, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. B.; Tamura, K.; André, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) PIK3CA-mutated advanced breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Kabos, P.; Chandarlapaty, S.; Neven, P.; Boni, V.; Lord, S.; Cartot-Cotton, S.; Celanovic, M.; Gosselin, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
    Meeting Abstract

    O'Shaughnessy, J.; Brufsky, A.; Rugo, H. S.; Tolaney, S. M.; Diab, S.; Punie, K.; Sardesai, S.; Hamilton, E.; Loirat, D.; Traina, T. A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
    Meeting Abstract

    Tsai, M.; Han, H. S.; Montero, A. J.; Tkaczuk, K. H.; Assad, H.; Pusztai, L.; Hurvitz, S. A.; Wilks, S. T.; Specht, J. M.; Nanda, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
    Meeting Abstract

    Swain, S. M.; Tan, A.; Gianni, L.; Kümmel, S.; Dang, C.; Schneeweiss, A.; O'Shaughnessy, J.; Liu, H.; Aguila, C.; Heeson, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of germline testing in patients with advanced cancers
    Journal Article

    Stadler, Z. K.; Maio, A.; Chakravarty, D.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; Tkachuk, K.; Fong, C. J.; Nguyen, B.; Erakky, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes of adult T-cell leukemia/lymphoma with allogeneic stem cell transplantation: Single-institution experience
    Journal Article

    Epstein-Peterson, Z. D.; Ganesan, N.; Barker, J. N.; Drullinsky, P. R.; Ghione, P.; Jakubowski, A. A.; Kumar, A.; Moskowitz, A. J.; Noy, A.; Perales, M. A.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Correspondence between clinician ratings of vulvovaginal health and patient-reported sexual function after cancer
    Journal Article

    Flynn, K. E.; Lin, L.; Carter, J.; Baser, R. E.; Goldfarb, S.; Saban, S.; Weinfurt, K. P.
    Journal of Sexual Medicine (2021)

    Fulltext@MSK | Save